Information Density: Genentech (Rozlytrek) – Signal Evidence & AI Readability

Genentech (Rozlytrek)

(https://rozlytrek.com) 📸 Data Snapshot: June 19, 2026
Information Density — The Lens

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Info Density Power-words vs. Substance ratio.
27 Impact Weight: 30 / 100
90% Reputation

The information density is exceptionally high regarding substance, with zero instances of marketing power words in the headings like revolutionary or world-class. Instead, headings like [H4] What is ROZLYTREK? and [H4] Important Safety Information lead into dense, specific clinical data including gene markers (ROS1, NTRK) and diagnostic criteria. However, a point penalty is applied for concept repetition, as the provided crawl shows identical text across all four URL slots, indicating a lack of unique content depth per sub-page.

Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.

📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://rozlytrek.com) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient
Medical Professional

Patients /
Our Medicines

[H1] Rozlytrek®
entrectinib

Full Prescribing Information

Patient Information

Instructions for Use | Capsules For Oral Use

Instructions for Use | Oral Pellets

[H2] Support & Resources

Report side effects for your Rozlytrek prescription

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here.

Get help paying for your Rozlytrek prescription

[H4] SUPPORT

Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT.
Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information.
Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine.

Get answers to your questions about your Rozlytrek prescription

[H4] SUPPORT

Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine.
Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form.

[H2] Indications & Important Safety Information

[H4] What is ROZLYTREK® (entrectinib)?

ROZLYTREK is a prescription medicine used to treat:

Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.
Adults and children 1 month of age and older with solid tumors (cancer) that:

are caused by certain abnormal NTRK genes, and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment.

It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors.
The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use.
[H4] Important Safety Information

What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including:

Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure:

persistent coughing or wheezing
trouble breathing when lying down
sudden weight gain
increasing shortness of breath
tiredness, weakness, or fatigue
swelling in ankles, feet, or legs

Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms.
Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.
Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems:

loss of appetite
nausea or vomiting
pain in the upper right stomach area
yellowing of your skin or the white part of your eyes
dark urine

Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia:

red, hot, tender, or swollen joints, especially in your big toe
pain in your stomach-area or sides
nausea or vomiting
pink or brown urine

Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation.
Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including:

double vision
blurry vision
new or increased floaters
seeing flashes of light
light hurting your eyes

Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK.
[H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:

have liver or kidney problems
have any heart problems, including a condition called long QT syndrome
have nervous system (neurological) problems
have or have had eye or vision problems
are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK.
Females who can become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK.
Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose.

Males with female partners that can become pregnant:

Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.
Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
[H4] What should I avoid while taking ROZLYTREK?

You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects.
Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve.

[H4] What are some possible side effects of ROZLYTREK?

[H4] The most common side effects of ROZLYTREK include:

tiredness
constipation
change in taste
swelling
dizziness
diarrhea
nausea
abnormal touch sensation
shortness of breath
muscle pain
confusion, mental status changes, memory problems, and hallucinations
weight gain
cough
vomiting
fever
joint pain
vision changes

These are not all the possible side effects of ROZLYTREK.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
SUB-PAGE (https://rozlytrek.com/patients/medicine-information-support/) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient
Medical Professional

Patients /
Our Medicines

[H1] Rozlytrek®
entrectinib

Full Prescribing Information

Patient Information

Instructions for Use | Capsules For Oral Use

Instructions for Use | Oral Pellets

[H2] Support & Resources

Report side effects for your Rozlytrek prescription

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here.

Get help paying for your Rozlytrek prescription

[H4] SUPPORT

Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT.
Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information.
Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine.

Get answers to your questions about your Rozlytrek prescription

[H4] SUPPORT

Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine.
Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form.

[H2] Indications & Important Safety Information

[H4] What is ROZLYTREK® (entrectinib)?

ROZLYTREK is a prescription medicine used to treat:

Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.
Adults and children 1 month of age and older with solid tumors (cancer) that:

are caused by certain abnormal NTRK genes, and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment.

It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors.
The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use.
[H4] Important Safety Information

What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including:

Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure:

persistent coughing or wheezing
trouble breathing when lying down
sudden weight gain
increasing shortness of breath
tiredness, weakness, or fatigue
swelling in ankles, feet, or legs

Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms.
Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.
Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems:

loss of appetite
nausea or vomiting
pain in the upper right stomach area
yellowing of your skin or the white part of your eyes
dark urine

Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia:

red, hot, tender, or swollen joints, especially in your big toe
pain in your stomach-area or sides
nausea or vomiting
pink or brown urine

Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation.
Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including:

double vision
blurry vision
new or increased floaters
seeing flashes of light
light hurting your eyes

Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK.
[H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:

have liver or kidney problems
have any heart problems, including a condition called long QT syndrome
have nervous system (neurological) problems
have or have had eye or vision problems
are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK.
Females who can become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK.
Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose.

Males with female partners that can become pregnant:

Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.
Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
[H4] What should I avoid while taking ROZLYTREK?

You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects.
Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve.

[H4] What are some possible side effects of ROZLYTREK?

[H4] The most common side effects of ROZLYTREK include:

tiredness
constipation
change in taste
swelling
dizziness
diarrhea
nausea
abnormal touch sensation
shortness of breath
muscle pain
confusion, mental status changes, memory problems, and hallucinations
weight gain
cough
vomiting
fever
joint pain
vision changes

These are not all the possible side effects of ROZLYTREK.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
SUB-PAGE (https://rozlytrek.com/patients/) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient
Medical Professional

Patients /
Our Medicines

[H1] Rozlytrek®
entrectinib

Full Prescribing Information

Patient Information

Instructions for Use | Capsules For Oral Use

Instructions for Use | Oral Pellets

[H2] Support & Resources

Report side effects for your Rozlytrek prescription

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here.

Get help paying for your Rozlytrek prescription

[H4] SUPPORT

Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT.
Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information.
Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine.

Get answers to your questions about your Rozlytrek prescription

[H4] SUPPORT

Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine.
Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form.

[H2] Indications & Important Safety Information

[H4] What is ROZLYTREK® (entrectinib)?

ROZLYTREK is a prescription medicine used to treat:

Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.
Adults and children 1 month of age and older with solid tumors (cancer) that:

are caused by certain abnormal NTRK genes, and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment.

It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors.
The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use.
[H4] Important Safety Information

What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including:

Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure:

persistent coughing or wheezing
trouble breathing when lying down
sudden weight gain
increasing shortness of breath
tiredness, weakness, or fatigue
swelling in ankles, feet, or legs

Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms.
Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.
Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems:

loss of appetite
nausea or vomiting
pain in the upper right stomach area
yellowing of your skin or the white part of your eyes
dark urine

Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia:

red, hot, tender, or swollen joints, especially in your big toe
pain in your stomach-area or sides
nausea or vomiting
pink or brown urine

Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation.
Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including:

double vision
blurry vision
new or increased floaters
seeing flashes of light
light hurting your eyes

Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK.
[H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:

have liver or kidney problems
have any heart problems, including a condition called long QT syndrome
have nervous system (neurological) problems
have or have had eye or vision problems
are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK.
Females who can become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK.
Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose.

Males with female partners that can become pregnant:

Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.
Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
[H4] What should I avoid while taking ROZLYTREK?

You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects.
Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve.

[H4] What are some possible side effects of ROZLYTREK?

[H4] The most common side effects of ROZLYTREK include:

tiredness
constipation
change in taste
swelling
dizziness
diarrhea
nausea
abnormal touch sensation
shortness of breath
muscle pain
confusion, mental status changes, memory problems, and hallucinations
weight gain
cough
vomiting
fever
joint pain
vision changes

These are not all the possible side effects of ROZLYTREK.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
SUB-PAGE (https://rozlytrek.com/patients/medicines/) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient
Medical Professional

Patients /
Our Medicines

[H1] Rozlytrek®
entrectinib

Full Prescribing Information

Patient Information

Instructions for Use | Capsules For Oral Use

Instructions for Use | Oral Pellets

[H2] Support & Resources

Report side effects for your Rozlytrek prescription

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here.

Get help paying for your Rozlytrek prescription

[H4] SUPPORT

Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT.
Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information.
Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine.

Get answers to your questions about your Rozlytrek prescription

[H4] SUPPORT

Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine.
Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form.

[H2] Indications & Important Safety Information

[H4] What is ROZLYTREK® (entrectinib)?

ROZLYTREK is a prescription medicine used to treat:

Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.
Adults and children 1 month of age and older with solid tumors (cancer) that:

are caused by certain abnormal NTRK genes, and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment.

It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors.
The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use.
[H4] Important Safety Information

What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including:

Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure:

persistent coughing or wheezing
trouble breathing when lying down
sudden weight gain
increasing shortness of breath
tiredness, weakness, or fatigue
swelling in ankles, feet, or legs

Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms.
Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.
Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems:

loss of appetite
nausea or vomiting
pain in the upper right stomach area
yellowing of your skin or the white part of your eyes
dark urine

Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia:

red, hot, tender, or swollen joints, especially in your big toe
pain in your stomach-area or sides
nausea or vomiting
pink or brown urine

Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation.
Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including:

double vision
blurry vision
new or increased floaters
seeing flashes of light
light hurting your eyes

Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK.
[H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:

have liver or kidney problems
have any heart problems, including a condition called long QT syndrome
have nervous system (neurological) problems
have or have had eye or vision problems
are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK.
Females who can become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK.
Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose.

Males with female partners that can become pregnant:

Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.
Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
[H4] What should I avoid while taking ROZLYTREK?

You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects.
Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve.

[H4] What are some possible side effects of ROZLYTREK?

[H4] The most common side effects of ROZLYTREK include:

tiredness
constipation
change in taste
swelling
dizziness
diarrhea
nausea
abnormal touch sensation
shortness of breath
muscle pain
confusion, mental status changes, memory problems, and hallucinations
weight gain
cough
vomiting
fever
joint pain
vision changes

These are not all the possible side effects of ROZLYTREK.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…